Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug development
Biotech
Boehringer digs in on ADCs with $991M AimedBio licensing accord
After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well.
Fraiser Kansteiner
Oct 15, 2025 10:05am
US biotechs thinking twice about licensing drugs to Europe
Sep 26, 2025 8:09am
Alternate history of NIH reveals potential impact of agency cuts
Sep 25, 2025 2:00pm
Pharma execs grilled by UK lawmakers over R&D pullback
Sep 16, 2025 12:27pm
Lilly invites biotechs to use AI platform to develop their drugs
Sep 9, 2025 7:43am
Servier hands Ideaya $210M upfront for ex-US rights to PKC asset
Sep 2, 2025 3:02pm
